Dr. Grace Yeh is one of the three founders, CEO and Chairperson of Onward Therapeutics SA since its inception in 2019. Currently, she is on the board of Biomunex Pharmaceuticals SAS and Emercell SAS in France. She also serves as Director, Taiwan Bio Industry Organization, and Executive Supervisor, Taiwan Women on Boards Association.

 

From 2003 to 2019, she was Founder, President and CEO of PharmaEngine, a publicly traded commercial stage oncology company (TWO:4162) headquartered in Taipei, Taiwan with a wholly owned subsidiary in Paris, France. Its market capitalization on the Taipei Exchange exceeded US$1 billion in 2015.

 

Prior to returning to Taiwan, she served in senior positions from 1988 to 2002, at Millennium Pharmaceuticals, LeukoSite, CytoMed, and T Cell Sciences, all based in Cambridge, MA, USA. Before joining the industry, she worked in academic research at INSERM (National Institutes of Health and Medical Research) in France; and Blond Mclndoe Centre for Transplantation Biology in England.

 

Approved products: ONYVIDE® and HENSIFY®.

 

Grace received her Ph.D. in Immunology from Medical University of South Carolina, USA. She was elected the Outstanding Alumni of Fu Jen Catholic University in 2015 and was given the EY Entrepreneur of the Year Award in 2016.  She also became the first female Laureate of the Industrial Technology Research Institute in 2021 among 49 male Laureates since its inception in 2012.

​

​